血凝素样氧化低密度脂蛋白受体-1心血管疾病-中华临床医师杂志.pdfVIP

²268 ² 中华临床医师杂志( 电子版)2017 年1 月第11 卷第2 期 Chin J Clinicians(Electronic Edition),January 15,2017,Vol.11,No.2 ²综述² 血凝素样氧化低密度脂蛋白受体-1 ：心血管疾病 治疗新靶点 焦云根 龚开政 赵培 王军 陈明星 吴丹 张振刚 【摘要】 血凝素样氧化低密度脂蛋白受体-1 （LOX-1 ）已经被证实是氧化低密度脂蛋白在内 皮细胞的主要受体，在内皮细胞功能不全、单核细胞黏附、泡沫细胞形成和动脉粥样斑块稳定性中 都发挥重要作用，而这些都是动脉粥样硬化进程中的重要事件。LOX-1在动脉粥样硬化、高血压病、 糖尿病等疾病病理过程中均表达升高，过去十几年的研究发现，包括他汀类药物、降血糖药物、抗 氧化和抗炎药物在内，越来越多的药物被证实能够抑制血管LOX-1 的表达和激活。因此，LOX-1 已 经成为心血管疾病令人关注的治疗靶点。本文就LOX-1在心血管疾病中的治疗策略进行综述。 【关键词】 C反应蛋白质； 过氧化物酶体增殖物激活受体； 血凝素样氧化低密度脂蛋白 受体-1 ； 他汀类 Lectin-like oxidized low-density lipoprotein receptor-1: a new therapeutic target for cardiovascular diseases Jiao Yungen, Gong Kaizheng, Zhao Pei, Wang Jun, Chen Mingxing, Wu Dan, Zhang Zhengang. Department of Cardiology, the Affiliated Hospital of Yangzhou University, Yangzhou 225001, China Corresponding author: Jiao Yungen, Email: ygjiao7906@163.com 【 Abstract 】 Lectin-like oxidized low-density lipoprotein (LOX-1) has been proved as the main receptor of oxidized low-density lipoprotein (Ox-LDL) in endothelial cells. LOX-1 is involved in endothelial dysfunction, monocyte adhesion, foam cell formation well as plaque stability; all of these events are critical in the progress of atherosclerosis. LOX-1 is up-regulated in the presence of pathological conditions including atherosclerosis, hypertension and diabetes. Over the past decade, increasing numbers of drugs including statins, anti-hyperglycemic drugs, anti-oxidants and anti-inflammatory agents have been demonstrated to inhibit vascular LOX-1 expression and activity. Therefore, LOX-1 represents an attractive therapeutic target for the treatment of human cardiovascular diseases. This review aimed to integrate the targeted therapy strategies of LOX-1 for cardiovascular diseases. 【Key words 】 C-reactive pr